Neurocritical Care News

The effect of levetiracetam, an antiseizure therapy, on high-frequency oscillation in patients with Alzheimer’s disease as well as epilepsy may prove its viability as a biomarker of disease pathology, according to data.

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.

Transplantation of neural stem cells improved neurologic and motor function for adults with chronic ischemic stroke at 12 months, according to a study presented at the International Stroke Conference.

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more than 44 pounds, according to the manufacturer.

RapidAI automated imaging appeared to be more accurate than VizAI in detecting cases of large vessel occlusion, as well as in identifying those missed by its counterpart among individuals with acute stroke, results of a comparative analysis show.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.

Introduction of cognitive processing therapy to treatment as usual was superior to standard treatment alone to address PTSD at 17 weeks, according to data published in JAMA Network Open.

An instructional video regarding two stroke-related mnemonics was linked to faster 911 call response for suspected stroke, according to a study presented at the International Stroke Conference.

A novel imaging analysis technique registered a high degree of sensitivity and specificity in identifying both presence and type of subdural hematoma, or SDH, data from a comparative analysis show.